April 22, 2020, the pharmaceutical company Roche announced results from the first part of the PASADENA study, a Phase II clinical trial (human study) of its potential Parkinson’s treatment prasinezumab. This therapy, which researchers call a monoclonal antibody, is one of many targeting the protein alpha-synuclein. Alpha-synuclein is the subject of intense interest by Parkinson’s researchers and the patient community, because it forms clumps in the brain that are suspected to be toxic and give rise to Parkinson’s disease.